Takeda's New Pharmaceutical Bulk Plant to be Constructed in Ireland.Business Editors and Health/Medical Writers OSAKA, Japan--(BW HealthWire)--March 27, 2002 Takeda Chemical Industries, Ltd. announced today that it decided to construct a new pharmaceutical bulk plant in Ireland as part of its global production network. The new plant will start operations in 2004 and is expected to make major contributions to product supply and cost competitiveness. Plant construction is planned to begin in October this year. Takeda formulated for·mu·late tr.v. for·mu·lat·ed, for·mu·lat·ing, for·mu·lates 1. a. To state as or reduce to a formula. b. To express in systematic terms or concepts. c. the 2001-2005 Medium-Term Management Plan and embarked on the challenge of becoming a major player in the global pharmaceutical market. To this end, the company is currently proactively engaged in reinforcing operating bases both domestically and overseas. The above mentioned plant construction and a smooth commencement of operation are therefore one of the key tasks of the medium-term management plan. The new Irish plant will be the first bulk plant constructed overseas by Takeda. Upon completion, it will, in combination with the Hikari Plant in Yamaguchi Prefecture, Japan, enhance the capacity of delivering bulk products on a global basis. Operations at the new plant will start with the production of drugs for clinical trials and the diabetes drug pioglitazone pioglitazone /pi·o·glit·a·zone/ (pi?o-glit´ah-zon) an antidiabetic agent that decreases insulin resistance in the peripheral tissues and liver; used as the hydrochloride salt in the treatment of type 2 diabetes mellitus. (trade name: Actos Actos® Pioglitazone, see there ) aimed at U.S. and European European emanating from or pertaining to Europe. European bat lyssavirus see lyssavirus. European beech tree fagussylvaticus. European blastomycosis see cryptococcosis. markets. Takeda has already established a pharmaceutical formulation Pharmaceutical formulation, in pharmaceutics, is the process in which different chemical substances are combined to a pure drug substance to produce a final medicinal product. and packaging plant in Ireland. The new bulk plant and the formulation/packaging plant will be run as separate companies. "The construction of the new bulk plant in Ireland is a vital step on the way to putting in place a global business structure," said Shozo Nakamura, Takeda managing director and general manager of the Pharmaceutical Production Division. "It will enable us to meet future growth in demand for our products, and ensure the stable supply of those products to the U.S. and European markets." Takeda's pharmaceutical production network currently spans Japan, Asia, and Italy and Ireland in Europe. The current operations in Ireland are responsible for the production of the diabetes drug pioglitazone (trade name: Actos), the hypertensive hypertensive /hy·per·ten·sive/ (-ten´siv) 1. characterized by increased tension or pressure. 2. an agent that causes hypertension. 3. a person with hypertension. drug candesartan candesartan /can·de·sar·tan/ (kan?de-sahr´tan) an angiotensin II receptor antagonist, used in the treatment of hypertension; administered orally as c. cilexetil. (trade name: Blopress, Amias, Kenzen, etc.), the peptic ulcer peptic ulcer: see ulcer. peptic ulcer Sore that develops in the mucous membrane of the stomach (more frequent in women) or duodenum (accounting for 80% of ulcers and more frequent in men) when its ability to resist acid in gastric juice is reduced. drug lansoprazole lansoprazole /lan·so·pra·zole/ (lan-so´prah-zol) a proton pump inhibitor used to inhibit gastric acid secretion for the treatment of duodenal or gastric ulcer, gastroesophageal reflux disease, and hyperchlorhydria. (trade name: Prevacid, Lansox, etc.) and other products, for U.S. and European markets. About Takeda Takeda is a research-based global company with its main focus on pharmaceuticals and is the largest pharmaceutical company in Japan and among the leaders in the world. Takeda discovers, develops, manufactures and markets a broad range of innovative products to contribute to better health and quality of life for people throughout the world. For more information, please see www.takeda.com. Outline of the New Plant
Company name Takeda Ireland Limited
(The formulation and packaging plant will change its
name from Takeda Ireland Limited to Takeda Ireland
Products Limited)
Location Clondalkin, South Dublin County
(Dublin suburbs)
Area 80,000 m2
Investment Approximately 80 million euros
Construction to start October 2002
Start of operations 2004
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion